• Explore /
  • Poster
  • / Ramucirumab, avelumab, and paclitaxel (RAP) as second-line treatment in gastro-esophageal adenocarcinoma, a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Ramucirumab, avelumab, and paclitaxel (RAP) as second-line treatment in gastro-esophageal adenocarcinoma, a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Abstract Video & Slides Poster

Authors

null

Peter C. Thuss-Patience

Charité–University Medicine Berlin, Department of Haematology, Oncology and Cancer Immunology, Campus Virchow-Klinikum, Berlin, Germany

Peter C. Thuss-Patience , Anica Högner , Eray Goekkurt , Michael Stahl , Albrecht Kretzschmar , Bärbel Schädlich , Thorsten Oliver Goetze , Gertraud Stocker , Peter Reichardt , Frank Kullmann , Daniel Pink , Prisca Bartels , Alexej Ballhausen , Armin Jarosch , Axel Hinke , Mascha Binder , Alexander Stein

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT03966118

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4051)

DOI

10.1200/JCO.2022.40.16_suppl.4051

Abstract #

4051

Poster Bd #

39

Abstract Disclosures

Similar Posters

First Author: Anica Högner

First Author: Peter C. Thuss-Patience

First Author: Sylvie Lorenzen

First Author: Emmanuelle Samalin